<?xml version="1.0" encoding="UTF-8"?>
<p id="par0055">Diagnostic tests were developed rapidly after the start of the SARS-CoV-2 outbreak allowing early recognition and detection of this novel virus. Nasopharyngeal swabs are the recommended specimen for molecular analysis. As of 19 March 2020, the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (
 <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html" id="intr0035" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html</ext-link>). Samples are collected from the upper respiratory tract (oropharyngeal and nasopharyngeal) and lower respiratory tract (endotracheal aspirate, expectorated sputum, or bronchoalveolar lavage) of patients suspected SARS-CoV-2 infection [
 <xref rid="bib0355" ref-type="bibr">71</xref>].
</p>
